Grand Brilliance Group Holdings Valuation
Is 8372 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8372 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 8372 (HK$0.09) is trading below our estimate of fair value (HK$0.3)
Significantly Below Fair Value: 8372 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8372?
Key metric: As 8372 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 8372's PE Ratio? | |
|---|---|
| PE Ratio | 8.8x |
| Earnings | HK$8.45m |
| Market Cap | HK$74.40m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.1x |
| Enterprise Value/EBITDA | 2.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 8372's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.7x | ||
574 Pa Shun International Holdings | 1.8x | n/a | HK$63.4m |
1110 Kingworld Medicines Group | 7.5x | n/a | HK$252.1m |
6833 Sinco Pharmaceuticals Holdings | 7.4x | n/a | HK$370.0m |
2427 Guanze Medical Information Industry (Holding) | 30.1x | n/a | HK$370.5m |
8372 Grand Brilliance Group Holdings | 8.8x | n/a | HK$74.4m |
Price-To-Earnings vs Peers: 8372 is good value based on its Price-To-Earnings Ratio (8.8x) compared to the peer average (11.7x).
Price to Earnings Ratio vs Industry
How does 8372's PE Ratio compare vs other companies in the HK Healthcare Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
574 Pa Shun International Holdings | 1.8x | n/a | US$8.15m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 8372 is good value based on its Price-To-Earnings Ratio (8.8x) compared to the Hong Kong Healthcare industry average (12.9x).
Price to Earnings Ratio vs Fair Ratio
What is 8372's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8372's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$4.10
7D
-5.7%
1Y
-48.6%
Sinopharm Group
HK$64.1b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.05
7D
-0.7%
1Y
0.3%
MicroPort Scientific
HK$11.0b
An investment holding company, engages in the manufacture, marketing, and sale of medical devices in the People’s Republic of China, North America, Europe, rest of Asia, South America, and internationally.
853
HK$5.70
7D
-7.8%
1Y
-55.5%